Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 18, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 11, 2021 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
Revolution Medicines to Participate in Upcoming Investor Conferences
March 09, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
February 18, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Global Bed Head Panel Market – Analysis and Demand with Forecast Overview to 2029 - by PMI
January 19, 2021 22:05 ET
|
PMI
Covina CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The global bed head panel market for US$ 2.0 billion in 2019 is anticipated to register a CAGR of 5.5%. The report " Global Bed Head Panel Market, By...
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
November 12, 2020 07:30 ET
|
Revolution Medicines, Inc.
Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination First-in-Class RAS(ON) Inhibitor Programs for Five Targets...
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 18, 2020 16:01 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...
Receptor Holdings Adds Alex Casdin to Board of Directors
April 08, 2019 08:50 ET
|
Receptor Holding
SEATTLE, April 08, 2019 (GLOBE NEWSWIRE) -- Alexander W. Casdin, Founder, CEO, and Portfolio Manager of Reneo Capital Management LP, has been named to the Board of Directors of Receptor Holdings...
Precision Medicine Market USD 88.64 Billion Revenue Witnesses High Demand due to Prevalence of Genetic Diseases Forecasts by 2022
September 04, 2018 11:02 ET
|
Market Research Future
Pune, India, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Market Research Future has released its report on the Global Precision Medicine Market which projects above-average growth and various market...
Yamaha FAZER Remotely Piloted Helicopter Receives FAA Approval
June 26, 2018 09:00 ET
|
Yamaha Motor Corp., USA
CYPRESS, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, has received an exemption from the Federal Aviation Administration (FAA) to begin using its FAZER remotely piloted...